Journal article
Rivaroxaban versus aspirin on functional and cognitive outcomes after embolic stroke of undetermined source: NAVIGATE ESUS trial
Abstract
BACKGROUND: The effect of interventions on functional impairment is an important outcome in stroke prevention trials and should be considered as an adjunct to counting discrete events. In the NAVIGATE-ESUS trial, 7213 patients with recent embolic strokes of undetermined source were randomized to rivaroxaban (15 mg once daily) or aspirin (100 mg daily). After 11 months there was no effect on the prevention of recurrent stroke.
AIMS: To determine …
Authors
Bosch J; Pearce LA; Sharma M; Canavan M; Whiteley WN; Mikulík R; Mundl H; Yusuf S; Hart RG; O'Donnell MJ
Journal
Journal of Stroke and Cerebrovascular Diseases, Vol. 31, No. 5,
Publisher
Elsevier
Publication Date
5 2022
DOI
10.1016/j.jstrokecerebrovasdis.2022.106404
ISSN
1052-3057